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Dogs are a major reservoir of Leishmania infantum, etiological agent of canine
leishmaniosis (CanL) a zoonotic visceral disease of worldwide concern. Therapeutic
protocols based on antileishmanial drugs are commonly used to treat sick dogs and
improve their clinical condition. To better understand the impact of Leishmania infection
and antileishmanial drugs on the dog’s immune response, this study investigates the
profile of CD4+ and CD8+ T cell subsets in peripheral blood, lymph node, and bone
marrow of sick dogs and after two different CanL treatments. Two CanL groups of
six dogs each were treated with either miltefosine or meglumine antimoniate combined
with allopurinol. Another group of 10 clinically healthy dogs was used as control. Upon
diagnosis and during the following 3 months of treatment, peripheral blood, popliteal
lymph node, and bone marrow mononuclear cells were collected, labeled for surface
markers CD45, CD3, CD4, CD8, CD25, and intracellular nuclear factor FoxP3, and T
lymphocyte subpopulations were immunophenotyped by flow cytometry. CanL dogs
presented an overall increased frequency of CD8+ and CD4+CD8+ double-positive
T cells in all tissues and a decreased frequency of CD4+ T cells in the blood.
Furthermore, there was a higher frequency of CD8+ T cells expressing CD25+FoxP3+
in the blood and bone marrow. During treatment, these subsets recovered to levels
similar to those of healthy dogs. Nevertheless, antileishmanial therapy caused an
increase of CD4+CD25+FoxP3+ T cells in all tissues, associated with the decrease of
CD8+CD25−FoxP3− T cell percentages. These findings may support previous studies
that indicate that L. infantum manipulates the dog’s immune system to avoid the
development of a protective response, ensuring the parasite’s survival and the conditions
that allow the completion of Leishmania life cycle. Both treatments used appear to
have an effect on the dog’s immune response, proving to be effective in promoting the
normalization of T cell subsets.
Keywords: antileishmanial therapy, bone marrow, canine leishmaniosis, effector T cells, flow cytometry, lymph
node, peripheral blood mononuclear cells, regulatory T (Treg) cells
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INTRODUCTION
Leishmaniosis is considered a neglected tropical disease (1) that
affects humans and domestic and sylvatic animals. Parasites
of the genus Leishmania are obligatory intracellular protozoa
and the etiological agent of this parasitic disease (2). The main
host cell for Leishmania parasites is the macrophage, which
the parasite is able to manipulate and prevent activation by
various mechanisms and, thus, avoid their intracellular death
and perpetuate the infection (3–5). Canine leishmaniosis (CanL),
endemic in about 50 countries and two major regions, South
America and the Mediterranean basin, is caused by Leishmania
infantum (6). Dogs affected by this disease can present a wide
variety of specific and unspecific clinical signs (7, 8). CanL
conventional treatments improve the clinical condition of dogs
and reduce the parasite burden (9). Although when therapy
is discontinued, relapses are common (10–12), indicating that
treatment does not promote parasite clearance in all cases.
Thus, it is important to improve the efficacy of the treatment
protocols applied to CanL to promote the clinical cure of the
dog, ensure parasite clearance, and prevent further transmission.
According to the most recent guidelines (8), the recommended
CanL treatment protocols combine allopurinol with either
meglumine antimoniate or miltefosine. Meglumine antimoniate
is a pentavalent antimonial considered a multifactorial drug
whose effects are still unclear. However, some authors have
referred the promotion of Leishmania DNA damage by oxidative
stress and influence on macrophage microbicidal activity (13–
15). Pentavalent antimonials, which belong to the same family
of meglumine antimoniate, such as sodium antimony gluconate,
have been shown to interfere with the host’s immune system by
activating macrophages to release interleukin 12 (IL-12), leading
to the subsequent production of interferon-γ (IFN-γ) by other
immune cells, that induce the phosphorylation of extracellular
signal-regulated kinase 1 (ERK-1) and ERK-2, driving the
production of reactive oxygen species (ROS) (16). Moreover, they
also appear to induce the expression of class I molecules of the
major histocompatibility complex (MHC), stimulating CD8+ T
cells that lead to apoptosis of infected cells (17, 18). Although
these drugs have proved antileishmanial activity in vitro and
in vivo, pentavalent antimonials have failed to treat visceral
leishmaniosis in human patients who are also infected with
HIV or receiving immunosuppressive therapy (17), indicating
that a complete cure is dependent on T cell-mediated responses
(19, 20). Miltefosine is an alkylphosphocholine compound able
to induce apoptosis by mechanisms still not entirely clear,
although the specific disturbance of the lipid content on the
parasite’s membrane and the modulation of macrophage activity
Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase;
BID, bis in die; BUN, blood urea nitrogen; CanL, canine leishmaniosis; CD, cluster
of differentiation; CG, control group; CVBD, canine vector-borne disease; DNA,
deoxyribonucleic acid; FMO, fluorescenceminus one; FoxP3, forkhead box protein
3; IFN-γ, interferon gamma; IL-2, interleukin 2; IL-10, interleukin 10; Megl+Al,
meglumine antimoniate with allopurinol; Milt+Al, miltefosine with allopurinol;
SID, semel in die; TGF-β, transforming growth factor beta; Th1, type-1 T-helper;
Th2, type-2 T-helper; TNF-α, tumor necrosis factor alpha; Treg cells, regulatory T
cells; UPC, urine protein-to-creatinine ratio.
are the most consensual modes of action (18, 21–24). Several
studies have reported the immunomodulatory properties of
miltefosine, with in vitro studies showing the induction of the
release of tumor necrosis factor α (TNF-α) and nitric oxide
(NO) by peritoneal macrophages of BALB/c mice (25) and
enhancement of IFN-γ receptors, thus restoring responsiveness
to this cytokine in macrophages infected by L. donovani
and promoting an IL-12-dependent Th1 response (26). Also,
in healthy human peripheral blood cells, it was found that
miltefosine was able to increase the production of IFN-γ, acting
as a co-stimulator of the IL-2-mediated T cell activation process,
together with increased expression of CD25, showing the possible
immunomodulatory activity of miltefosine (27). Allopurinol, a
purine analog of adenosine nucleotide, blocks RNA synthesis,
inhibiting Leishmania growth (28, 29). To date, meglumine
antimoniate or miltefosine in combination with allopurinol are
both considered first-line treatments in Europe (7, 8). Recently,
in Brazil, miltefosine therapy was approved for CanL treatment
(30). Taking into account the emergence of a greater number
of reports on drug resistance, whether it be in humans or dogs
(13, 17, 21, 31), it is crucial to deepen the understanding of the
mode of action of the most used antileishmanial therapies.
In dogs, disease outcome is mainly determined by the cell-
mediated immune response, with T cells playing a key role
in cytokine release, which interacts with infected macrophages,
influencing macrophage activation and subsequent killing of
internalized parasites. According to the cytokine environment,
naive CD4+ T lymphocytes can differentiate into a protective
subset (Th1) or a Th2 cell subset, which favors the progress
of infection (32). A protective Th1 immune response is
characterized by a high production of pro-inflammatory
cytokines as is the case of IFN-γ, TNF-α, and IL-2. These
cytokines stimulate the cytotoxic activity of CD8+ T cells and
activate macrophage respiratory burst, leading to the synthesis of
ROS and induce NO production, which can cause major damage
to the parasite membrane, leading to the death of the parasite
(32–34). On the other hand, a Th2 response directs the release
of anti-inflammatory cytokines and stimulates the humoral
immune response, favoring the establishment of infection and
disease exacerbation (6, 7). Previous works on symptomatic dogs
with CanL have demonstrated that the lack of adequate cell-
mediated immune response might be associated with decreased
levels of CD4+ T cells and high antibody titers (35–38). In
vitro studies of cytotoxic CD8+ T cells from asymptomatic dogs
demonstrated a role in resistance to CanL by enhancing IFN-γ
production and causing the lysis of infected macrophages (39).
A critical role of immune regulation has been attributed to a
subgroup of cells denominated regulatory T (Treg) cells, which
seem to be recruited to the sites of Leishmania infection, enabling
parasite survival and ensuring the transmission cycle (40, 41).
Experimental studies of cutaneous leishmaniosis performed in L.
major-infected mice showed that Treg cells are essential for the
development and maintenance of persistent cutaneous disease
(40). The fast increase of CD4+CD25+ Treg cells at the sites
of L. major infection suppressed parasite-eliminating immune
mechanisms (41). Accumulation of IL-10-producing Treg cells
observed in the bone marrow of patients with L. donovani
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visceral leishmaniosis can cause immunosuppression, prevent
the release of pro-inflammatory cytokines, like IFN-γ, avoid
macrophage activation, and be associated with unresponsiveness
to treatment (42). Another study showed increased CD4+CD25+
Treg cells exhibiting high levels of Forkhead box Protein 3
(FoxP3) gene expression along with transforming growth factor
β (TGF-β) in spleen and draining lymph nodes of BALB/c
mice infected with L. infantum (43). This cell subpopulation
contributes to immunosuppression and control of parasite-
mediated immunopathology during infection. Treg cell subsets
that constitutively express CD25 and synthesize IL-10 and TGF-
β drive the suppression of cell-mediated immune responses (44).
These cells are considered potent suppressors of the activation
of CD8+ T cells (45). Nevertheless, another study showed a
reduced percentage of CD3+CD4+FoxP3+ Treg cells in dogs
infected with L. infantum, independently of antibody titer (46).
Although CD8+ T suppressor cells have been identified, their
mode of action and purpose are not fully understood (47).
Some studies have shown that resting CD4+ lymphocytes are
resistant to CD8+CD25+FoxP3+ Treg cells, which indicates that
the initiation of cell-mediated immune response is not likely to
be affected by CD8+ Treg cells. In contrast, CD8+ Treg cells
can play a critical role in suppressing ongoing CD4+ T cell
responses (48). Besides, the activity of CD4+CD25+FoxP3+ Treg
cells appears to be mediated through the release of immune-
suppressive cytokines and by cell contact-dependentmechanisms
(48). With regard to leishmaniosis, few studies focus on Treg
cells, and less are those that have analyzed the CD8+ Treg cell
fraction. Tiwananthagorn et al. (49) reported that in the liver
of L. donovani-infected mice, CD4+FoxP3+ Treg cells, but not
CD8+FoxP3+ T cells, are essential for the increased susceptibility
to Leishmania infection and high IL-10 production.
T cells expressing both CD4 and CD8 molecules have been
identified in peripheral blood and secondary lymphoid organs
of several species, such as pigs, monkeys, humans, chickens,
rats, mice, and dogs (50–56). These CD4+CD8+ double-positive
(dp) T cells appear to constitute memory CD4+ helper T
cells that, upon activation, develop the ability to express the
CD8α chain and, in cases such as pigs, produce high levels
of IFN-γ in response to stimulation with viral antigens (50).
This subpopulation has been identified as being increased in
chronic diseases, such as cancer, autoimmune diseases, and
viral infections (57–61). Several studies have also reported the
presence of CD25 and FoxP3 in dp T cells of dogs, revealing a
possible regulatory activity among this subpopulation (62, 63).
Thus, the current study aims to evaluate the kinetics of
CD4+ and CD8+ T cell subsets in tissues that commonly harbor
Leishmania parasites in both sick and treated dogs. Sick dogs
(CanL) were treated by two of the most used protocols for CanL
during a 3-month period, and peripheral blood, lymph node, and
bone marrow T cells were immunophenotyped.
MATERIALS AND METHODS
Dog Selection
Twenty-three household dogs living in the endemic area of
the Metropolitan Region of Lisbon (Portugal) were diagnosed
with CanL at clinical stage I/II, according to the LeishVet
Consensus Guidelines (64), and at stage C, following the
Canine Leishmaniasis Working Group Guidelines (65). Twelve
of these sick dogs fulfilled the minimum requirements to
enter the study (Figure 1), which included having at least
1.5 years of age, weighing more than 5 kg, not having been
vaccinated for leishmaniosis, being negative for circulating
pathogens potentially responsible of canine vector-borne diseases
(CVBDs), and have not undergone any treatment in the last 8
months that could interfere with the immune response (such as
corticosteroids, antibiotics, or immunomodulators). The present
study also included a control group of 10 clinically healthy dogs
that were negative for Leishmania antibodies and other CVBDs
and not vaccinated for leishmaniosis. All dog owners gave written
consent after being informed about the objectives of the study
and every procedure. The selected animals included 15 males
and 7 females of various breeds, with ages ranging between
2 and 9 years and weight between 7.6 and 32.1 kg. Clinical
examination and sample collection were done by veterinarians
at the Teaching Hospital of the Faculty of Veterinary Medicine,
University of Lisbon.
As previously described by our group (66), dogs diagnosed
with CanL that presented biochemical parameters such as
increased blood urea nitrogen (BUN), creatinine, and/or alanine
aminotransferase (ALT), aspartate aminotransferase (AST), and
urine protein-to-creatinine (UPC) ratio between 0.2 and 0.6,
which point to the possibility of developing hepatic and renal
lesions, were treated with miltefosine [Milteforan R©, Virbac S.A.,
France; 2 mg/kg per os, semel in die (SID) for 4 weeks] combined
with allopurinol [Zyloric R©, Laboratórios Vitória, Portugal; 10
mg/kg, per os, bis in die (BID) for at least 6 months] and
correspond to Group Milt+Al. Dogs that exhibited changes in
serum proteins and UPC ratios between 0.2 and 0.4 were treated
with meglumine antimoniate (Glucantime R©, Merial Portuguesa,
Portugal; 100 mg/kg SID for 4 weeks) combined with allopurinol
(10 mg/kg, per os, BID for at least 6 months) and were included
in Group Megl+Al. To prevent new infections during the study
and Leishmania transmission, deltamethrin-impregnated collars
were applied to all dogs.
Experimental Design
To investigate the effect of Leishmania infection and
antileishmanial treatments in helper, cytotoxic, and regulatory
T cell subsets, peripheral blood, popliteal lymph node, and
bone marrow mononuclear cells were isolated from sick
dogs (CanL) before the beginning of treatment (M0) and
monthly after treatment (M1, M2, and M3). These cells were
immunophenotyped by evaluating the surface expression
of CD45, CD3, CD4, CD8, and CD25 and the intracellular
expression of FoxP3. To reduce the number of animals
used in this study and to ensure any ethical concern for
animal discomfort and well-being, the amount of sample
collection and its periodicity were reduced to a minimum.
Furthermore, peripheral blood, popliteal lymph node, and
bone marrow samples were collected from sick dogs before
the onset of treatment (M0) to establish the baseline levels of
cell populations, avoiding the need of an additional group of
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FIGURE 1 | Dog selection diagram used in the current study. From a population of dogs living in an endemic area of zoonotic visceral leishmaniosis (ZVL), two groups
clinically diagnosed with canine leishmaniosis (CanL) were established and treated with either miltefosine in combination with allopurinol (Milt+Al) or meglumine
antimoniate in association with allopurinol (Megl+Al). A group of clinically healthy dogs and free of any canine vector-borne disease (CVBD) was also selected as the
control group.
untreated sick dogs. Peripheral blood, popliteal lymph node,
and bone marrow samples were also collected from clinically
healthy dogs [control group (CG)]. The present study followed
the directive 86/609/EEC of the Council of the European Union
and was approved by the Ethics and Animal Welfare Committee
of the Faculty of Veterinary Medicine, University of Lisbon.
Isolation of Peripheral Blood, Lymph Node,
and Bone Marrow Mononuclear Cells
Peripheral blood mononuclear cells were obtained through
density gradient centrifugation (Histopaque R©-1077 solution,
Sigma-Aldrich, Germany). Dog peripheral blood was
resuspended in PBS (1:1 v/v), overlaid on half of that total
volume in Histopaque R©-1077 solution and centrifuged 400 ×
g for 30min at 18◦C. Peripheral blood mononuclear cells were
then harvested at the interface of PBS and Histopaque R© and
washed twice in cold PBS (300 × g, 10min, 4◦C). Whenever
red blood cells were still visible in the pellet, a step of lysis
was done by adding 5ml of RBC Lysis Buffer (eBioscience,
USA) for 5min and stopping the reaction with 10ml of PBS,
followed by a centrifugation at 300 × g (4◦C) for 10min. The
pellet was then resuspended in Flow Cytometry Staining Buffer
(FCSB) (eBioscience), and the total volume was adjusted for 2
× 107 cells ml−1. Lymph node and bone marrow aspirates were
centrifuged at 400 × g (4◦C) for 5 and 15min, respectively, and
resuspended in FCSB with the total volume also adjusted for
2 × 107 cells ml−1. These samples were then kept on ice until
antibody labeling.
Flow Cytometry
To characterize regulatory and effector T cell subpopulations, a
multicolor panel was designed for flow cytometry analysis, and
each fluorochrome-conjugated antibody was titrated for optimal
staining (Table 1). Cell suspensions (50 µl) were incubated
with the following monoclonal antibodies (30min at 4◦C in
the dark): rat anti-dog CD45 (clone YKIX716.13, eBioscience
Inc.), mouse anti-dog CD3 (clone CA17.2A12, AbD Serotec,
UK), anti-dog CD4 (clone YKIX302.9, eBioscience Inc.), rat anti-
dog CD8 (clone YCATE55.9, AbD Serotec), and mouse anti-dog
CD25 (clone P4A10, eBioscience Inc.) (Table 2). Then, cells were
washed twice with 1ml of FCSB and centrifuged at 400 × g
(4◦C) for 5min. Afterward, 1ml of FoxP3/Transcription Factor
Fixation/Permeabilization Working Solution (eBioscience Inc.)
was added, and cells were incubated overnight at 4◦C in the
dark. Next, 500 µl of 1× Permeabilization Buffer (eBioscience
Inc.) was added, and cells were centrifuged at 400 × g (4◦C)
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TABLE 1 | Flow cytometer setup, fluorochrome panel, and labeling.
Instrument: Beckman Coulter Cyan ADP
Laser lines 405 nm 488 nm 642 nm
Emission filters 450/50 530/40 575/25 680/30 665/20 750LP
Fluorochrome eFluor® 450 FITC PE PerCP/Cy5.5 APC Alexa Fluor® 700
Biomarker CD45 CD3 CD25 FoxP3 CD4 CD8
Brightness
Antibody rat anti-dog mouse anti-dog mouse anti-dog anti-mouse/rat rat anti-dog rat anti-dog
Clone YKIX716.13 CA17.2A12 P4A10 FJK-16s YKIX302.9 YCATE55.9
Company eBiosciences AbD Serotec eBioscience eBioscience eBioscience AbD Serotec
Volume 5 µl per test (1:20) 8 µl per test (1:12.5) 5 µl per test (1:20) 5 µl per test (1:20) 5 µl per test (1:20) 10 µl per test (1:50)
The green-shaded squares indicate the level of brightness for each corresponding fluorochrome, from dim (1 square) to the brightest (5 squares).
TABLE 2 | Fluorochrome compensation panel graph by sample type and tissue.
Sample type Marker Blood Lymph node Bone marrow
CD45 CD3 CD4 CD8 CD25 FoxP3







FMO-CD25 X X X
FMO-FoxP3 X X X
All X X X
The green-shaded slots indicate the antibody label used in each sample type, while the crosses indicate which samples were analyzed in each tissue.
for 5min, followed by two washes at 400 × g (4◦C) for 5min
with 1ml of 1× Permeabilization Buffer and a last washing
step with 500 µl of FCSB. Cells were resuspended in a total
of 100 µl of FCSB and incubated for 15min at 4◦C in the
dark. Intracellular staining with anti-mouse/rat FoxP3 (clone
FJK-16s, eBioscience Inc.) monoclonal antibody was done by
incubating for at least 30min (4◦C) in the dark, followed by
two washes with 1× Permeabilization Buffer at 400 × g (4◦C)
for 5min. For flow cytometry acquisition (three-laser equipped
CyAn ADP apparatus, Beckman Coulter, using the Summit v4.3,
Dako Colorado Inc. software), cells were resuspended in a final
volume of 300µl of FCSB. For each sample, a minimum of 20,000
gated events were acquired, and data analysis was performed
using FlowJo version 10.0.7 (Tree Star, CA). To define the best
gating strategy to be applied (Figure 2), compensation was done
with unstained, single-stained, and “fluorescence minus one”
(FMO) samples (Table 2).
A recent study (67) showed relevant proof that the
doublet discrimination usually made in flow cytometry
analysis, with the reasoning that they constitute experimental
artifacts, may hide cell-to-cell contact, in particular, T
cell–monocyte association that is not disrupted during
sample processing. Thus, in the current study, a simple
approach was used to compare the frequency of doublets in
healthy, sick, and treated dogs following the gating strategy
shown in Figure 3A.
Statistical Analysis
Statistical analysis between control, infected, and treated groups
was performed using GraphPad Prism software package (version
8.0.1, GraphPad Software Inc.). The Kolmogorov–Smirnoff test
was used to assess data normality. The non-parametric Kruskal–
Wallis Test (one-way ANOVA on ranks) with Dunn’s post
hoc test was used to evaluate differences in cell subset levels
between sick, treated, and control groups. Lastly, the repeated
measures ANOVA test with Tukey’s post hoc test was used
to compare dogs between the several months M0, M1, M2,
and M3.
RESULTS
Canine Leishmaniosis Promotes a High
Frequency of Cell Doublets That Reach
Healthy Values During Treatment
A significant increase of events in the doublets gate in both blood
(pMilt+Al = 0.0459; pMegl+Al = 0.0143) (Figure 3B) and lymph
node (pMilt+Al = 0.0484; pMegl+Al = 0.0062) (Figure 3C) was
observed in sick dogs (M0) when compared with the control
group. One month after Milt+Al treatment (M1), blood (p =
0.0126), lymph node (p= 0.0293), and bonemarrow (p= 0.0147)
presented a significantly high frequency of doublets. Although,
during treatment, doublets return to frequencies close to those
of the control group. In dogs treated with Megl+Al, peripheral
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FIGURE 2 | Gating strategy. Peripheral blood sequential gating strategy for a panel of six antibodies to identify the different cell subpopulations after doublet
exclusion. CD45, a pan-leukocyte marker, and CD3, a T-lymphocyte specific marker, were used to define the T-lymphocyte population, with posterior separation of
CD4+ and CD8+ cells, CD4+CD8+ double-positive T cells, and subsequent regulatory CD25+FoxP3+ and effector CD25−FoxP3− cells. Red histograms from
unstained control samples and colored histograms from single-stained control samples were used to define the sequential gating, along with gray histograms from
fluorescence minus one (FMO) controls to gate for rare cells (CD25+FoxP3+).
blood exhibited significantly high percentages of doublets in
the first (pM1 = 0.02) and second (pM2 = 0.0118) months of
treatment. On the other hand, the bone marrow presented only a
transient increase of doublets 2 months (pM2 = 0.0301) after the
beginning of the treatment (Figure 3D).
Canine Leishmaniosis Chemotherapy
Causes an Imbalance of T Lymphocyte
Population
Peripheral blood (Figure 4A) and lymph node (Figure 4B) of
dogs with active leishmaniosis (M0) presented T lymphocyte
(CD45+CD3+) levels similar to clinically healthy dogs. However,
the subsequent administration of either treatment resulted in
lymphocyte frequency reduction. Dogs under Megl+Al therapy
showed a significant reduction of the percentage of blood
T cell population (CD45+CD3+ cells) after 2 (pM2 = 0.0239)
and 3 (pM3 = 0.0046) months of treatment. However, in the
lymph node, a significant frequency reduction of the T cell
population was observed at 1 (pM1 = 0.0319) and 2 (pM2 =
0.0328) months with this therapy. Furthermore, bone marrow
T cells (Figure 4C) frequency significantly increased after the
first month of treatment with Megl+Al (pM1 = 0.0399), reaching
values similar to clinically healthy dogs by the second month
(M2). One month after the beginning of treatment with Milt+Al,
a transient reduction of lymph node T cells (pM1 = 0.0467) was
observed. The bone marrow, in turn, showed a transient higher
frequency of T cells (pM2 = 0.0459) 2 months after treatment,
recovering to levels identical to those of control dogs in the third
month (M3).
Anti-leishmanial Therapy Favors the
Predominance of CD4+ T Cells Over CD8+
T Cells
According to several authors, the CD4+/CD8+ T cell ratio
acquired by flow cytometry analysis can be considered a simple
and fast way to assess cell-mediated immune response (65, 68).
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FIGURE 3 | Doublet analysis. (A) Gating strategy example in the blood of a healthy [control group (CG)] and a sick dog (M0). Percentage of doublets gated on total
events for blood (B), lymph node (C), and bone marrow (D) before and after the beginning of treatment. Results of 22 dogs are represented by box and whisker plots
and median, minimum, and maximum values. The non-parametric Kruskal–Wallis test (one-way ANOVA on ranks) with Dunn’s post hoc test was used for statistical
comparisons between treatment groups and the control group (CG). The repeated measures ANOVA test with Tukey’s post hoc test was used for statistical
comparisons inside each treatment group. p-values are indicated in every statistically significant comparison.
FIGURE 4 | Frequency of lymphocytes (CD45+CD3+) in the blood (A), lymph node (B), and bone marrow (C) of healthy [control group (CG)], sick (M0), and treated
dogs (M1, M2, and M3). Results of 22 dogs are represented by box and whisker plots and median, minimum, and maximum values. The non-parametric
Kruskal–Wallis test (one-way ANOVA on ranks) with Dunn’s post hoc test was used for statistical comparisons between treatment groups and the CG. The repeated
measures ANOVA test with Tukey’s post hoc test was used for statistical comparisons inside each treatment group. p-values are indicated in every statistically
significant comparison.
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When compared with healthy dogs, blood (pM0 = 0.0177)
(Figure 5A), and lymph node (pM0 = 0.0246) (Figure 5B) cells
of sick dogs presented a significant decrease of the CD4/CD8
ratio to values close to 1, pointing to similar frequencies of CD8+
and CD4+ T cells. During treatment, this ratio progressed toward
values closer to 2, indicating the predomination of CD4+ T cells.
On the other hand, the bone marrow CD4+/CD8+ T cell ratio
(Figure 5C) of sick dogs was similar to that of healthy dogs, with
ratios ranging between 0.5 and 1. These values point toward a
variation between a slight predomination of CD8+ T cells and an
identical frequency of both T cell subsets.
Canine Leishmaniosis Increases
CD4+CD8+ Double-Positive T Cell
Frequency in Peripheral Blood, Lymph
Node, and Bone Marrow
Sick dogs (M0) showed increased frequencies of CD4+CD8+
dp T cells in the blood (Figure 6A) (pMilt+Al = 0.0182;
pMegl+Al = 0.0015), lymph node (Figure 6B) (pMilt+Al = 0.0234;
pMegl+Al = 0.0318), and bone marrow (Figure 6C) (pMilt+Al
= 0.005; pMegl+Al = 0.006) when compared to healthy dogs.
The administration of either treatment protocol resulted in a
maintenance of these high frequencies of CD4+CD8+ dp T
cells in all tissues during the first month of treatment (M1),
progressively normalizing by the following month (M2), with
the exception of lymph node of dogs treated with the Megl+Al
protocol that recovered 1 month after treatment.
CD4+CD8+ Double-Positive T Cells
Expressing Regulatory Phenotype
Decrease in Peripheral Blood of Sick Dogs
and Increase in the Lymph Node and Bone
Marrow After Treatment
Lymph node (Figure 6E) and bone marrow (Figure 6F) of sick
dogs showed a significant frequency reduction of dp T cells
expressing CD25 molecules (lymph node: pMilt+Al = 0.0024;
pMegl+Al = 0.0319/bone marrow: pMilt+Al = 0.0018; pMegl+Al =
0.0293), which recovered to values similar to clinically healthy
dogs during treatment. However, in peripheral blood, treatment
caused a significant decrease of this T cell subset (Figure 6D).
In turn, the percentage of CD25+FoxP3+ dp T cells in the
blood of sick dogs (Figure 6G) was higher than that in healthy
dogs (pMilt+Al = 0.0484; pMegl+Al = 0.0095), while being similar
to the control group in the lymph node (Figure 6H) and bone
marrow (Figure 6I). Treated dogs presented a normalization
of the frequencies in the blood after 1 month of treatment,
while showing a progressive increase in this subpopulation,
reaching higher frequencies than the control group, in the
lymph node (pMilt+Al = 0.0072; pMegl+Al = 0.0061) and
bone marrow (pMilt+Al = 0.0310; pMegl+Al = 0.0411) in the
third month.
Leishmania Infection Results in the
Increase of Blood CD8+ T Cell Frequencies
With CD25+FoxP3+ Phenotype
Blood of sick dogs (M0) exhibited a significant decrease in the
frequency of the CD4+ T cell subset (pMilt+Al = 0.0253; pMegl+Al
= 0.0467) (Figure 7A) along with a high frequency of the CD8+
T cell subset (pMilt+Al = 0.0018; pMegl+Al = 0.0052) (Figure 7B).
Both treatments were able to recover normality for the CD4+
and CD8+ T cell fractions. However, dogs under the Megl+Al
protocol recovered to values similar to those of clinically healthy
dogs during the first month of treatment (M1), faster than the
group treated with Milt+Al that only recovered after the second
month (M2).
The frequency of blood T cells with CD4+CD25+ phenotype
showed some fluctuation, mainly during Megl+Al treatment
(Figure 7C), although with no statistical differences when
compared with clinically healthy dogs. However, a significant
increase in the frequency of the CD8+CD25+ T cell subset
(pMilt+Al = 0.0071; pMegl+Al = 0.0246) was observed in sick dogs
FIGURE 5 | CD4/CD8 ratio in the blood (A), lymph node (B), and bone marrow (C) of healthy [control group (CG)], sick (M0), and treated dogs (M1, M2, and M3).
Results of 22 dogs are represented by mean values ± SEM. The non-parametric Kruskal–Wallis test (one-way ANOVA on ranks) with Dunn’s post hoc test was used
for statistical comparisons between treatment groups and the CG. The repeated measures ANOVA test with Tukey’s post hoc test was used for statistical
comparisons inside each treatment group. p-values are indicated in every statistically significant comparison.
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FIGURE 6 | Frequency of CD4+CD8+ double-positive (dp) T cells. The frequency of dp T cells (A–C) expressing CD25 (D–F) and CD25 and FoxP3 (G–I) was
evaluated in the peripheral blood (A,D,G), lymph node (B,E,H), and bone marrow (C,F,I) of healthy [control group (CG)], sick (M0), and treated dogs (M1, M2, and
M3). Results of 22 dogs are represented by box and whisker plots and median, minimum, and maximum values. The non-parametric Kruskal–Wallis test (one-way
ANOVA on ranks) with Dunn’s post hoc test was used for statistical comparisons between treatment groups and the CG. The repeated measures ANOVA test with
Tukey’s post hoc test was used for statistical comparisons inside each treatment group. p-values are indicated in every statistically significant comparison.
(M0) when compared with that of the control group (Figure 7D).
This cell subset returned to normal values immediately after the
beginning of both treatments (M1).
CD4+CD25+FoxP3+ (pMilt+Al = 0.0411; pMegl+Al = 0.0310)
and CD8+CD25+FoxP3+ (pMilt+Al = 0.0118; pMegl+Al = 0.0052)
T cell subsets of sick dogs (M0) presented higher frequencies than
those of the control group (Figures 7E,F). After administration
of both treatments, an increase in the frequency of the
CD4+CD25+FoxP3+ T cell subset was observed (pMilt+Al(M1)
= 0.0092; pMegl+Al(M2) = 0.0029), with the values returning to
healthy levels at M2 and M3, for the Milt+Al and Megl+Al
groups, respectively. Likewise, the CD8+CD25+FoxP3+ T cell
subset recovered to values comparable to those of control dogs
after 3 months for both treatment protocols.
Effector T cell subsets of sick dogs (M0) presented different
patterns. CD4+CD25−FoxP3− T cells were significantly lower
than those of the control group (pMilt+Al = 0.0086; pMegl+Al
= 0.0073). However, dogs recovered to healthy values 1
month after the beginning of treatment with Megl+Al (M1)
and after 2 months of Milt+Al therapy (M2) (Figure 7G).
On the other hand, CD8+CD25−FoxP3− T cells of sick
dogs were similar to those of healthy dogs, but subsequent
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FIGURE 7 | Frequency of CD4+ (A), CD8+ (B), regulatory (CD25+FoxP3+) (C–F), and effector (CD4+CD25−FoxP3−/CD8+CD25−FoxP3−) (G,H) T lymphocytes in
the blood of healthy [control group (CG)], sick (M0), and treated dogs (M1, M2, and M3). Results of 22 dogs are represented by box and whisker plots and median,
minimum, and maximum values. The non-parametric Kruskal–Wallis test (one-way ANOVA on ranks) with Dunn’s post hoc test was used for statistical comparisons
between treatment groups and the CG. The repeated measures ANOVA test with Tukey’s post hoc test was used for statistical comparisons inside each treatment
group. p-values are indicated in every statistically significant comparison.
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treatments led to a significant reduction in cell frequency
(pMilt+Al(M1) = 0.0046; pMegl+Al(M1) = 0.026), with the
Megl+Al group recovering to normal frequencies by the third
month (M3) and the Milt+Al group after the second month
(M2) (Figure 7H).
Canine Leishmaniosis Promotes the
Increase of Lymph Node CD8+ T Cell
Frequencies, and Treatment Leads to an
Imbalance of Effector and Regulatory
T Cell Subsets
In the lymph node of sick dogs, the frequency of CD4+ T
cells was similar to that of healthy dogs (Figure 8A), but the
CD8+ T cell fraction presented a higher percentage (pMilt+Al =
0.0052; pMegl+Al = 0.0120) (Figure 8B). Furthermore, treatment
administration caused a reduction of the CD8+ T cell frequencies
to values similar to control dogs. Three months after the onset
of treatment with Megl+Al, the CD4+ T cell fraction was
significantly diminished (p = 0.0389) when compared with
clinically healthy dogs.
In sick dogs, the level of CD4+ (Figure 8C) and CD8+
(Figure 8D) T cells with CD25+ phenotype was similar to healthy
dogs. However, both treatment protocols led to a transient
increase of the CD4+CD25+ T cell subset frequencies after 1
month of Milt+Al treatment (p = 0.0463) and 2 months of
Megl+Al (p = 0.0471). The CD8+CD25+ T cell subpopulation
of dogs under the Milt+Al protocol showed a significant increase
2 (p = 0.0200) and 3 (p = 0.0071) months after the beginning of
treatment (Figure 8D).
Likewise, sick dogs showed similar frequencies of
CD4+CD25+FoxP3+ and CD8+CD25+FoxP3+ T cells
compared to healthy dogs. Moreover, after treatment, these
dogs exhibited a significant increase in the frequency of the
CD4+CD25+FoxP3+ T cell subset (Figure 8E). In dogs treated
with Milt+Al, a peak of the frequency of CD4+ Treg cells
was observed 2 months (pM2 = 0.0182) after the beginning of
treatment. One and 2 months after administration, Megl+Al
also promoted a CD4+ Treg frequency increase (pM1 = 0.0172;
pM2 = 0.0098) that subsequently reverted to normal values.
Moreover, Milt+Al caused a significant increase in the frequency
of CD8+CD25+FoxP3+ T cells (pM1 = 0.0027; pM2 = 0.0071;
pM3 = 0.0145), while the Megl+Al protocol only resulted in a
transient increase of this subpopulation 1 month after treatment
(pM1 = 0.0399) (Figure 8F).
Effector T cell subsets in the lymph node of sick dogs
were similar to those of healthy dogs. After treatment
administration, CD4+CD25−FoxP3− T cell frequencies showed
a progressive reduction during the first and second month
with both the Milt+Al (pM1 = 0.0301; pM2 = 0.0434) and the
Megl+Al protocol (pM1 = 0.0225; pM2 = 0.0212) (Figure 8G).
CD8+CD25−FoxP3− T cell frequencies also presented a
significant reduction after drug administration (pMilt+Al =
0.0134; pMegl+Al = 0.0021), with the Milt+Al-treated dogs
recovering cell frequency levels by the second month (M2) and
the Megl+Al-treated dogs by the third month (M3) (Figure 8H).
Leishmania Infection Causes the Increase
of Bone Marrow CD8+ T Cell Frequencies
With CD25+FoxP3+ Phenotype
In the bone marrow of sick dogs, the frequency of CD4+ T
cells (Figure 9A) was similar to clinically healthy dogs. The
administration of Milt+Al did not cause significant alterations
in the CD4+ T cell fraction, while dogs under the Megl+Al
protocol exhibited a transient frequency increase (p = 0.0134)
2 months after the onset of treatment. Meanwhile, a prominent
increase of the frequency of CD8+ T cells was observed in sick
dogs (pMilt+Al = 0.0293; pMegl+Al = 0.0495) (Figure 9B). This
high frequency of CD8+ T cells in the bone marrow persisted
during both treatments (Milt+Al: pM1 = 0.0367; pM2 = 0.0310)
(Megl+Al: pM1 = 0.0463; pM2 = 0.0411), returning to values
similar to control dogs by the third month (M3).
Regarding the CD4+CD25+ T cell subpopulation
(Figure 9C), no considerable differences were observed in
the bone marrow of sick dogs when compared with that of
clinically healthy dogs. Moreover, dogs treated with Megl+Al
evidenced a transient decrease of the frequency of CD8+CD25+
T cells by month 2 (pM2 = 0.0367) that quickly recovered
(Figure 9D).
In the bone marrow of sick dogs, the frequency of Treg
cells (CD4+CD25+FoxP3+) was similar to that of control dogs
(Figure 9E). Nevertheless, an increase of the frequency of this
cell subset was observed 1 month (pMilt+Al = 0.0484; pMegl+Al
= 0.0484) after either treatment, followed by normalization.
Similar to peripheral blood, the CD8+CD25+FoxP3+ T cell
subset frequencies (Figure 9F) of sick dogs was significantly
higher (pMilt+Al = 0.0086; pMegl+Al = 0.0389). Both treatments
led to a reduction of cell frequencies to values similar to those of
the control group.
CD4+CD25−FoxP3− T cell frequencies of sick dogs were
significantly lower in comparison with those of healthy dogs
(pMilt+Al = 0.0232; pMegl+Al = 0.0016) (Figure 9G). However,
the Megl+Al group recovered to values close to those of healthy
dogs 1 month earlier than the Milt+Al group. The frequencies of
CD8+CD25−FoxP3− T cells of sick dogs, on the other hand, were
similar to those of healthy dogs, with the administration of either
treatment leading to a significant decrease 1 (pMilt+Al = 0.0439;
pMegl+Al = 0.0147) and 2 months (pMilt+Al = 0.0095; pMegl+Al =
0.0484) after the beginning of treatment (Figure 9H).
DISCUSSION
CanL treatment has an inherent connection with the ability of the
dog’s immune system to develop a competent cellular immune
response against L. infantum. Thus, comprehending the cellular
immune response and the dynamics of T cell subsets in dogs
naturally infected with Leishmania, especially in organs that
usually harbor these parasites, is of utmost relevance not only for
the treatment and management of CanL but also as guidelines
for the development of prophylactic and therapeutic tools. A
better knowledge of the effect of antileishmanial therapy on the
cellular immune response of dogs can facilitate the development
of strategies to reduce the transmission of the parasite and,
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FIGURE 8 | Frequency of CD4+ (A), CD8+ (B), regulatory (CD25+FoxP3+) (C–F), and effector (CD4+CD25−FoxP3−/CD8+CD25−FoxP3−) (G,H) T lymphocytes in
the lymph node of healthy [control group (CG)], sick (M0), and treated dogs (M1, M2, and M3). Results of 22 dogs are represented by box and whisker plots and
median, minimum, and maximum values. The non-parametric Kruskal–Wallis test (one-way ANOVA on ranks) with Dunn’s post hoc test was used for statistical
comparisons between treatment groups and the CG. The repeated measures ANOVA test with Tukey’s post hoc test was used for statistical comparisons inside each
treatment group. p-values are indicated in every statistically significant comparison.
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FIGURE 9 | Frequency of CD4+ (A), CD8+ (B), regulatory (CD25+FoxP3+) (C–F), and effector (CD4+CD25−FoxP3−/CD8+CD25−FoxP3−) (G,H) T lymphocytes in
the bone marrow of healthy [control group (CG)], sick (M0), and treated dogs (M1, M2, and M3). Results of 22 dogs are represented by box and whisker plots and
median, minimum, and maximum values. The non-parametric Kruskal–Wallis test (one-way ANOVA on ranks) with Dunn’s post hoc test was used for statistical
comparisons between treatment groups and the CG. The repeated measures ANOVA test with Tukey’s post hoc test was used for statistical comparisons inside each
treatment group. p-values are indicated in every statistically significant comparison.
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consequently, lead to a decrease in the incidence of zoonotic
visceral leishmaniosis. Therefore, in the current study, T cell
subpopulations of dogs naturally infected with L. infantum were
phenotypically characterized before treatment and during the
influence of antileishmanial drugs.
In the current study, it was found that sick dogs have
increased doublet frequencies in peripheral blood and lymph
node, decreasing to values similar to clinically healthy dogs
after treatment. As was proposed by Burel et al. (67), these
changes in the doublet levels associated with CanL and during
the first months of treatment may reflect a possible cell-to-cell
interaction between T lymphocytes and antigen-presenting cells.
It is also possible that the doublets could increase as a result
of interaction of Treg:lymphocyte, as Treg cells, which seem to
be increased in CanL, appear to exert immune suppression by
mechanisms dependent on cell contact (69). In the present work,
it was not possible to delve deeper into these interactions since
this was a secondary objective of the study. In this sense, not
enough events were collected in the doublet region to obtain
meaningful information on further subpopulations. This way,
further detailed studies are needed to corroborate this hypothesis,
with the correlation between CanL and the level of doublets
being able to be used as a possible marker of disease to monitor
treatment success and predict potential relapses (67).
Several authors have correlated symptomatic dogs with
decreased levels of CD4+ T cells and CD4/CD8 ratios in
peripheral blood (35, 70), along with high antibody titers. Other
authors verified that higher infectivity to sand flies by naturally
infected dogs was associated with lower proportions of CD4+
T cells in the blood (37). Furthermore, it has also been shown
that the administration to dogs infected with Leishmania of
antileishmanial drugs, such as amphotericin B and meglumine
antimoniate, promoted the increase of the percentage and the
absolute cell count of CD4+ T cells in the blood, respectively
(36, 71). On the other hand, other treatment protocols, such
as allopurinol in monotherapy, although able to improve the
number of circulating CD4+ T cells in the blood, were not
able to restore values to those within the normal range (68).
Thus, the findings obtained in the current study are in line with
previous reports. Sick dogs presented low CD4/CD8 ratios in
peripheral blood and lymph node, recovering to values equal to
the healthy group after the administration of both treatments.
Following our results, and according to several authors (36–
38, 68, 71), the CD4/CD8 ratio can be a useful indicator of the
immunological condition of sick dogs and a possible tool with
prognostic value. Some authors also describe a decline of the
percentage of CD3+ lymphocytes in the peripheral blood of CanL
symptomatic dogs, as a direct consequence of the reduction in
the frequency of CD4+ T cells (36, 56). Other authors, on the
contrary, have reported a significant increase of CD3+ T cells in
sick dogs, especially in dogs severely affected (72). Nevertheless,
the administration of antileishmanial therapy in both situations
restored CD3+ lymphocytes within normal values (36, 56, 72).
Moreover, the results of the present study point to a dual effect of
antileishmanial therapy on bone marrow and lymph node. Both
treatments led to a reduction in the frequency of lymph node T
cells (CD45+CD3+) along with an increase in the bone marrow.
Interestingly, only meglumine antimoniate in association with
allopurinol resulted in a decrease of the frequency of blood
T cells.
Protective immunity against CanL is usually considered to be
dependent on a Th1 immune response (6). The predominance
of IFN-γ-producing CD4+ T cells is crucial for macrophage
activation in order to kill internalized Leishmania through the
production of NO and ROS (73, 74). A reduction of the CD4+
T cell population is usually associated with the inability to
control the infection, allowing the survival and replication of
Leishmania parasites in macrophages, which can subsequently
lead to increased infectibility to sand flies (37). Murine studies
have shown that Leishmania parasites negatively interfere with
the ability of IFN-γ to induce the expression of MHC-II mRNA,
leading to parasitized macrophages with a low expression of
MHC class II molecules (75). Thus, due to their reduced capacity
as antigen-presenting cells, these macrophages are therefore
unable to provide co-stimulatory signals to CD4+ T cells (76, 77),
which, in turn, are not stimulated, do not proliferate, and do
not produce IFN-γ. Although the complete role of CD8+ T cells
in CanL is still debated, there are studies of leishmaniosis in
humans and mice showing a functional duality. CD8+ T cells
can either play a protective role by releasing IFN-γ, or they can
be pathogenic to the host, causing excessive inflammation at
the site of infection (73) as a result of cytotoxic activity, which
can exacerbate disease progression (78). Following the results of
previous reports (35, 36, 79), the sick dogs included in the current
study also showed an increased frequency of CD8+ T cells in the
blood, lymph node, and bone marrow, along with significantly
decreased levels of CD4+ T cells in the blood. These findings
suggest that CD8+ T cells are at the forefront of the fight against
Leishmania infection, especially in tissues that commonly harbor
Leishmania parasites. Nonetheless, antileishmanial therapy led to
the recovery of the T cell population in all tissues. And whether
due to the direct action of the antileishmanial drugs or the
availability of free antigens as a consequence of Leishmania’s
death caused by therapy, a shift of T cell population occurs,
leading to a rapid reduction in the frequency of CD8+ T cells in
the blood and lymph node.
Regulatory T cells are generally considered to be a subset
of CD4+ T cells, which express the non-constitutive IL-2R-α
chain (CD25) and the transcriptional factor FoxP3 (80, 81). The
main function of these cells is to suppress excessive or misguided
immune responses and prevent autoimmune diseases (74, 82).
Few are the Treg studies done in CanL, which account for
the lack of overall information on these subpopulations (83).
In dogs experimentally infected with L. infantum, FoxP3 RNA
was increased in the skin and liver, but in the lymph node, the
authors verified a decrease associated with disease progression
(84). Figueiredo et al. (85) referred that CanL enhanced FoxP3
expression in the jejunum and colon. However, the skin of L.
chagasi (syn. L. infantum)-infected dogs revealed lower levels
of FoxP3 expression (86). Another study found no correlation
between TGF-β or IL-10 producing CD4+ Treg cells in the blood
and spleen and the parasitic load of naturally infected dogs (87).
In the present study, sick dogs showed increased frequencies
of blood CD4+ Treg cell associated with decreased percentages
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of CD4+ (CD25−FoxP3−) effector T cells, signaling a lack
of adequate cellular immune response, which can prolong
the presence of the parasite, facilitating parasite transmission.
Antileishmanial therapy allowed the normalization of blood
CD4+ Treg and effector T cell subsets, especially in dogs under
the meglumine plus allopurinol protocol, restoring the action of
CD4+ effector T cells.
Curiously, and following the obtained results, CanL does
not seem to cause significant changes in CD4+ Treg cells and
CD4+ effector T cell subsets of lymph nodes. Similarly, in a
study with mice infected with L. infantum, a high frequency
of CD4+CD25+ T cells expressing FoxP3 was found in the
lymph nodes in the first weeks of infection, followed by a
decrease in the subsequent chronic phase of the disease (43),
supporting the observed results in the present study. In addition,
the administration of CanL drugs caused a transient disturbance
in Treg cells and effector T cell subsets. By directing the reduction
in the frequency of effector T cells associated with the increase of
the Treg cell subset, therapy appears to promote the development
of a suppressive immune response located in the dog’s lymph
node. Despite this, 3 months after the start of treatment,
the values normalize. Therefore, it is possible that miltefosine
and meglumine antimoniate, which were administered to sick
dogs only during the first 4 weeks of treatment, are primarily
responsible for the development of a suppressive immune
response that can limit inflammation.
In patients with visceral leishmaniosis caused by L.
donovani, the bone marrow revealed an increase of Treg
cells (CD4+CD25+FoxP3+) that outnumbered effector T cells
(CD4+CD25+FoxP3−) (42). These Treg cells were shown to be
a source of IL-10 and persisted in patients even after successful
chemotherapy with sodium antimony gluconate. In the current
study, both treatments induced a quick increase in the frequency
of the CD4+CD25+FoxP3+ and CD4+CD25−FoxP3− T cell
subsets in the bone marrow of dogs, but for a short period of
time, normalizing by the second month of observation. In this
case, the findings support the hypothesis that the increase in the
frequency of CD4+ Treg cells can be a possible consequence of
miltefosine and meglumine antimonial drugs.
In CanL, as in other diseases in which the immune system
is deeply involved, the presence and action of CD8+ Treg
cells are still a matter of discussion. In a study of human
visceral leishmaniosis, the authors proposed that IL-10 produced
by CD8+ T cells could lead to a downregulation of cytokine
production, in particular pro-inflammatory cytokines like TNF-
α and IFN-γ, blocking this way the anti-leishmanial macrophage
activity (88). Subsequent studies have shown the presence of a
subset of CD8+ Treg cells that can inhibit the CD4+ T cell-
mediated immune response by inducing apoptosis of activated
CD4+ T cells (89). This way, the increased frequency of the
CD8+CD25+FoxP3+ T cell subset in the blood and bonemarrow
of sick dogs shown in the current study could represent a
complementarymechanism of immune regulation thatmay favor
parasite survival (78). Treatment of CanL with miltefosine or
meglumine antimoniate in combination with allopurinol directs
blood CD8+ Treg cells to progressively return to normal values.
These antileishmanial drugs seem to cause a shift in blood and
bone marrow lymphocytes by reducing the increased frequency
of the CD8+CD25+FoxP3+ T cell subset and reduce effector
CD8+ (CD25−FoxP3−) T cells to restrain the local inflammatory
immune response and cytotoxicity in order to lessen possible
tissue damage.
CD4+CD8+ dp T cells have been identified in dogs with and
without CanL (56, 90, 91). In the current study, the frequency
of CD4+CD8+ dp T cell subsets was revealed to be increased
in peripheral blood, lymph node, and bone marrow of dogs
with CanL. Considering the chronic profile of CanL, these
findings are in line with previous studies (57–61) that have
established a link between increased dp T cells and chronic
diseases. Furthermore, dp T cells have also been associated with
increased production of IFN-γ in pigs (50), similar to previous
results found in dogs with CanL (66). Moreover, the presence
of CD4+CD8+CD25+FoxP3+ T cell subset in the peripheral
blood of sick dogs reveals a possible regulatory activity, as
proposed by other authors (62), while the lymph node and bone
marrow presented decreased percentages of CD25, reflecting a
possible cytotoxic role (63) resulting from the infection with L.
infantum. In turn, in the present study, the administration of
either treatment led to a change in both profiles, with dp T cells
in the blood losing the regulatory phenotype, possibly in order
to fight the infection, while the lymph node and bone marrow
apparently switching to a regulatory profile to nullify a possible
excessive cytotoxic damage. In any case, since the role of these
CD4+CD8+ dp T cells is not yet fully understood in vivo, further
in-depth studies are still needed in these subpopulations in order
to elucidate their modes of action.
The immune response to Leishmania, in humans, mice, or
dogs, seems to be far complex and influenced by several types
of immune cells and different immune mediators, establishing
an elaborate network. Either way, there seems to be a consensus
that Leishmania parasites lead to differentiation of specific cell
immunophenotypes in different tissues. CanL in this study led
to an increased frequency of CD8+ T cells in all tissues, along
with increased CD4+CD8+ dp T cell frequencies, resulting
in a predominant pro-inflammatory profile. CD8+ Treg cell
frequencies were also significantly increased in the blood and
bone marrow, showing a possible action on immune responses
mediated by CD4+ T cells, which can lead to parasite tolerance
and disease progression. In the present work, the administration
of either treatment protocol led to an overall recovery of the
T cell subpopulations by the end of observation, reflecting the
clinical improvement of the dogs (66). Nonetheless, it should be
noted that both protocols resulted in an increase of CD4+ Treg
cell frequencies in all tissues, possibly in order to significantly
reduce the frequency of CD8+CD25−FoxP3− T cells present and
to control the local inflammatory immune responses. Lastly, with
respect to the effectiveness of either treatment, despite not being
the scope of this work, the recovery of many subpopulations
was achieved more quickly with the Megl+Al protocol than
with the Milt+Al protocol, which is in agreement with previous
results (66).
Monitoring T cell subsets by using specific biomarkers and
analyzing the effectiveness of CanL treatments allow a better
understanding of the interplay between the parasite and the dog’s
immune response, which should improve patient management,
lead to the development of more efficient and less toxic
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chemotherapies, and encourage the use of prophylactic measures
that favor the reduction of zoonotic visceral leishmaniasis.
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